Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature

Arcari Annalisa; Bassi Simona; Pochintesta Lara; Trabacchi Elena; Moroni Carlo Filippo; Rossi Angela; Zanlari Luca; Vallisa Daniele

doi:10.1016/j.lrr.2017.11.001

Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature

Leuk Res Rep. 2017 Nov 15:8:21-23. doi: 10.1016/j.lrr.2017.11.001. eCollection 2017.

Authors

Arcari Annalisa¹, Bassi Simona¹, Pochintesta Lara¹, Trabacchi Elena¹, Moroni Carlo Filippo¹, Rossi Angela², Zanlari Luca³, Vallisa Daniele¹

Affiliations

¹ Hematology Unit and Transplantion Center, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
² Transfusional Centre and Immunohematology, Immunogenetics Laboratory, "Guglielmo da Saliceto" Hospital, via Taverna 49, 29100 Piacenza, Italy.
³ Department of Internal Medicine, Valdarda Hospital, via Roma 6, 29017 Fiorenzuola d'Arda, Piacenza, Italy.

Abstract

The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a "real life" situation.

Keywords: Allogeneic hematopoietic stem cell transplantation; B-cell receptor inhibitors; Chronic lymphocytic leukemia; TP53 mutation.

Publication types

Case Reports